Janmaat, Maarten L <br/><br/>
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Apr 2006 
 - 1612-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2005.03.4900  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Class I Phosphatidylinositol 3-Kinases<br/>ErbB Receptors--antagonists & inhibitors<br/>Esophageal Neoplasms--drug therapy<br/>Extracellular Signal-Regulated MAP Kinases--metabolism<br/>Female<br/>Gefitinib<br/>Gene Dosage<br/>Genes, ras<br/>Humans<br/>Male<br/>Middle Aged<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Phosphorylation<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Quinazolines--adverse effects